Key result
Preoperative ECMO as a bridge to definitive cardiac surgery resulted in a 25% 30-day mortality, significantly lower than the 77% EuroSCORE 2-predicted mortality (MD 42.33; 95% CI 36.86-47.98; P<0.001).
Why the study?
Does venoarterial ECMO as a bridge to definitive cardiac surgery improve survival compared to predicted mortality in critically ill, otherwise inoperable patients with cardiogenic shock?
Observational (n=12)
Yes
Does venoarterial ECMO as a bridge to definitive cardiac surgery improve survival compared to predicted mortality in critically ill, otherwise inoperable patients with cardiogenic shock?
Mean Difference: 42.33 (95% CI 36.86–47.98)
Absolute Event Rate: 25% vs 77%
p-value: p=< 0.001
VA-ECMO can be successfully utilized as a bridge to conventional cardiac surgery in critically ill patients with cardiogenic shock, resulting in significantly lower 30-day mortality than predicted by risk models.
Clinical clause:* Suggests VA-ECMO may serve as a viable bridge.
Extracorporeal membrane oxygenation (ECMO) offers an opportunity for patient recovery through complete cardiopulmonary support but is associated with complications that limit duration and overall utility. We examine the role of ECMO as a potential bridge to high-risk cardiac surgery in otherwise inoperable cases. This study reports a retrospective, multi-institution experience examining all patients for whom ECMO was used preoperatively as a bridge to definitive cardiac surgery without exception. A consecutive patient database (December 2011 through August 2017) was utilized. European System for Cardiac Risk Evaluation (EuroSCORE) 2 was calculated as a metric of patient acuity and risk assessment. Observed and expected mortality were compared. Twelve adult patients fit inclusion criteria and were supported with ECMO during the study period. There were five males and seven females. Average age was 56 (39-77) years. All 12 patients were supported with venoarterial ECMO for cardiogenic shock. This was done in preparation for corrective conventional cardiac surgery. Definitive cardiac surgical procedures included complex valve (n = 5), left ventricular assist device (n = 3), coronary artery bypass grafting (CABG; n = 2), CABG/ventricular septal defect repair (n = 1), and mitral valve replacement/CABG (n = 1). Average time of ECMO support was 200 (range 113-379) hours. Three patients were decannulated from ECMO at the conclusion of definitive cardiac surgery. Risk assessed by Logistic EuroSCORE 2 ranged from 64% to 89%. Average EuroSCORE 2-predicted mortality representing all 12 patients was 77%. Thirty day mortality was 25% (3/12), and hospital mortality was 33% (4/12). Seven patients are still alive today, with a mean survival of 37 (range 2-64) months. Two deaths were associated with gastrointestinal bleeding and two with evolving liver failure. Mean difference between the EuroSCORE 2 prediction model and actual observed 30 day mortality rate was 42.33 (95% CI 36.86-47.98) with a two-tailed, one-sample t test value of p < 0.001. ECMO can successfully be utilized as a bridge to conventional cardiac surgical procedures in critically ill patients, with a historically high mortality.
No takes yet. Share an insight, caveat, or question.
Dobrilovic et al. (2017) conducted an observational in Cardiogenic shock requiring bridge to definitive cardiac surgery (n=12). Extracorporeal membrane oxygenation (ECMO) vs. EuroSCORE 2-predicted mortality was evaluated on 30 day mortality (MD 42.33, 95% CI 36.86-47.98, p=< 0.001). Preoperative ECMO as a bridge to definitive cardiac surgery resulted in a 25% 30-day mortality, significantly lower than the 77% EuroSCORE 2-predicted mortality (MD 42.33; 95% CI 36.86-47.98; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: